ArticleEClinicalMedicine2023

Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1/2b randomized placebo-controlled trial.

Natalie I Mazur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.